Mount Sinai Launches PrIME Trials for Faster Studies
The new Precision Immunology and Experimental Medicine Trial Organization aims to shorten the time needed to start early-phase clinical trials.
Updated on Nov. 20, 2026 in Biotech

Mount Sinai launched the Precision Immunology and Experimental Medicine Trial Organization (PrIME Trials), a new initiative within the Marc and Jennifer Lipschultz Precision Immunology Institute at the Icahn School of Medicine. PrIME Trials initiated a Sanofi-sponsored first-in-human in vivo CAR-T trial in less than 60 days.
Why it matters
Mount Sinai states that the time it takes to start clinical trials is one of the biggest barriers to new treatments, and PrIME Trials offers a coordinated pathway for academic and industry partners to address it. The initiative aims to accelerate therapies targeting the underlying causes of inflammatory and autoimmune diseases.
The first major trial uses an investigational in vivo CAR-T therapy, a form of immune-cell treatment, and was started through FASTrack within 60 days. The source does not disclose efficacy data, and it is unclear how the therapy's performance will be measured.
The players
Mount Sinai
Mount Sinai is a New York City-based health system whose Icahn School of Medicine houses the new PrIME Trials initiative.
Sanofi
Sanofi is a global pharmaceutical company that sponsored the first-in-human in vivo CAR-T trial run through PrIME Trials.
The details
PrIME Trials integrates with Mount Sinai's OCCAM Immune research platform, allowing investigators to study how individual patients' immune systems respond to treatment. Its first major study is a Sanofi-sponsored, first-in-human trial led by Margrit Wiesendanger with Jacques Azzi as co-investigator, with rapid activation supported by the CTrials program at BRANY.
Timeline
PrIME Trials launch was announced by Mount Sinai on November 20, 2026.
The first major trial was initiated in less than 60 days after the launch.
Roadmap
The PrIME launch builds on FASTrack, Mount Sinai's process for starting complex clinical trials within 60 days or less, which now is being applied to an in vivo CAR-T study. The initiative places an institutional trial-acceleration model at the center of efforts to move immune-based therapies from research into patient testing.
Patients with inflammatory or autoimmune conditions could eventually see new therapies reach clinical testing sooner if trial start-up delays are reduced. The source does not indicate when any PrIME-supported treatment would become available.
The takeaway
Shortening trial start-up time is a practical lever for getting new immune-based treatments to patients sooner. Watch whether PrIME's 60-day model produces measurable gains across future trials.
Further reading
Explore more Biotech developments shaping clinical research in New York City.
More information
Learn more on the PrIME Trials program information page.
Source note: This article includes information reported by The Manila times.






